1,644,804 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets bought a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,644,804 shares of the biopharmaceutical company's stock, valued at approximately $41,959,000. BNP Paribas Financial Markets owned approximately 0.28% of Royalty Pharma as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Barclays PLC lifted its stake in Royalty Pharma by 16.3% during the third quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company's stock worth $8,737,000 after purchasing an additional 43,339 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Royalty Pharma during the 3rd quarter worth $61,000. Franklin Resources Inc. lifted its position in shares of Royalty Pharma by 5.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock worth $40,705,000 after buying an additional 70,130 shares during the last quarter. GAMMA Investing LLC grew its position in Royalty Pharma by 31.4% in the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 590 shares during the last quarter. Finally, Ridgewood Investments LLC raised its stake in Royalty Pharma by 40.8% during the fourth quarter. Ridgewood Investments LLC now owns 30,735 shares of the biopharmaceutical company's stock worth $784,000 after acquiring an additional 8,913 shares in the last quarter. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $32.76 on Thursday. The business has a 50 day moving average of $32.41 and a 200-day moving average of $29.69. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company has a market capitalization of $18.88 billion, a P/E ratio of 22.59, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a $0.22 dividend. The ex-dividend date is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.69%. Royalty Pharma's payout ratio is 60.69%.

Wall Street Analysts Forecast Growth

Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Royalty Pharma presently has a consensus rating of "Buy" and a consensus price target of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.